论文部分内容阅读
本文采用正常人外周血单个核细胞，经加用ＣＤ３单克隆抗体，辅以少量ＩＬ－２共同培养，制备ＣＤ３单抗激活杀伤（ＣＤ３ＡＫ）细胞。通过对４５例中、晚期癌肿患者临床试用，初步观察并分析了该项治疗临床疗效及意义。结果表明ＣＤ３ＡＫ细胞治疗的临床总有效率为５３．３％；不同肿瘤间有效率无明显差异；细胞输注总量的增加及多次输注者，临床有效率明显提高；接受该项治疗患者，机体ＮＫ细胞活性增强，ｓＩＬ－２Ｒ浓度下降，而治疗前后ｍＩＬ－２Ｒ、ＴＮＦ水平未见明显差异。
In this study, normal human peripheral blood mononuclear cells were used to produce CD3 monoclonal antibody activated killer (CD3AK) cells by adding CD3 monoclonal antibody and co-cultured with a small amount of IL-2. Through clinical trials of 45 patients with advanced and advanced cancer, the clinical efficacy and significance of the treatment were initially observed and analyzed. The results showed that the total effective rate of CD3AK cell therapy was 53.3%; there was no significant difference in the efficiency of different tumors; the increase in the total amount of cell infusion and multiple infusions, the clinical efficiency was significantly improved; patients receiving the treatment The activity of NK cells increased and the concentration of sIL-2R decreased. There was no significant difference in mIL-2R and TNF levels before and after treatment.